Lupus trials recruiting in Illinois

All Lupus trials nationally

Cities in Illinois

Recruiting trials in Illinois

• A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
  NCT06557265 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
  NCT07328581 · Phase: Phase 2 · Ages: 16 Years to 70 Years · Sex: All (male and female) · Illinois: Chicago
• A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
  NCT06925542 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Illinois: Chicago
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
  NCT06411249 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Morton Grove, Rockford
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female) · Illinois: Willowbrook
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Willowbrook
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
  NCT06581198 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
  NCT07607964 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Orland Park
• A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
  NCT06977724 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Illinois: Orland Park
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female) · Illinois: Chicago, Willowbrook
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
  NCT07430306 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Illinois: Willowbrook
• A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
  NCT07085104 · Phase: Phase 1 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Illinois: Chicago
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
  NCT06897930 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Illinois: Chicago
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · Illinois: Chicago
• Lupus Landmark Study: A Prospective Registry and Biorepository
  NCT05934149 · Phase: Not specified · Ages: 18 Years to 110 Years · Sex: All (male and female) · Illinois: Chicago
• Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
  NCT06133972 · Phase: Phase 3 · Ages: 12 Years to 100 Years · Sex: All (male and female) · Illinois: Skokie, Willowbrook
• Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
  NCT00198068 · Phase: Not specified · Ages: 18 Years to 45 Years · Sex: Female · Illinois: Chicago
• RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
  NCT06121297 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Illinois: Chicago
• Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
  NCT05268289 · Phase: Phase 2 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Illinois: Hinsdale
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago
• The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
  NCT05538208 · Phase: Phase 2 · Ages: 8 Years to 20 Years · Sex: All (male and female) · Illinois: Chicago
• VIBRANT: VIB4920 for Active Lupus Nephritis
  NCT05201469 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Illinois: Chicago